tradingkey.logo

Co-Diagnostics Inc

CODX
0.390USD
-0.016-3.87%
Close 11/10, 16:00ETQuotes delayed by 15 min
14.13MMarket Cap
LossP/E TTM

Co-Diagnostics Inc

0.390
-0.016-3.87%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Co-Diagnostics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Co-Diagnostics Inc's Score

Industry at a Glance

Industry Ranking
133 / 209
Overall Ranking
311 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
2.000
Target Price
+392.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Co-Diagnostics Inc Highlights

StrengthsRisks
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.92M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.92M.
Overvalued
The company’s latest PE is -0.35, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.32M shares, increasing 11.14% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 561.02K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.46.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 162.91K, representing a year-over-year decrease of 93.87%, while its net profit experienced a year-over-year decrease of 1.72%.

Score

Industry at a Glance

Previous score
6.29
Change
0

Financials

8.73

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.82

Operational Efficiency

2.57

Growth Potential

5.19

Shareholder Returns

7.11

Co-Diagnostics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.74, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.35, which is -43.88% below the recent high of -0.20 and -1920.08% above the recent low of -7.16.

Score

Industry at a Glance

Previous score
6.74
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 133/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Co-Diagnostics Inc is 2.00, with a high of 3.00 and a low of 1.00.

Score

Industry at a Glance

Previous score
7.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
2.000
Target Price
+392.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Co-Diagnostics Inc
CODX
2
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.43, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 1.20 and the support level at -0.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.42
Change
0.01

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.032
Neutral
RSI(14)
48.280
Neutral
STOCH(KDJ)(9,3,3)
9.997
Oversold
ATR(14)
0.180
High Vlolatility
CCI(14)
-39.707
Neutral
Williams %R
93.819
Oversold
TRIX(12,20)
0.605
Buy
StochRSI(14)
37.770
Sell
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
0.392
Sell
MA10
0.436
Sell
MA20
0.437
Sell
MA50
0.401
Sell
MA100
0.339
Buy
MA200
0.388
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 13.08%, representing a quarter-over-quarter decrease of 50.50%. The largest institutional shareholder is The Vanguard, holding a total of 1.71M shares, representing 2.84% of shares outstanding, with 47.28% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Orca Capital GmbH
2.19M
--
The Vanguard Group, Inc.
Star Investors
1.73M
-2.53%
Private Advisory Group LLC
1.18M
--
Egan (Dwight H.)
748.18K
+17.54%
Abbott (Richard David)
631.47K
+2.07%
Brown (Brian Lee)
599.30K
+16.76%
Renaissance Technologies LLC
Star Investors
561.02K
+1.94%
BlackRock Institutional Trust Company, N.A.
427.44K
-13.95%
Geode Capital Management, L.L.C.
319.99K
-6.48%
Nelson (James B)
272.50K
+21.56%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 1.37, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.37
Change
0
Beta vs S&P 500 index
1.16
VaR
+7.67%
240-Day Maximum Drawdown
+78.15%
240-Day Volatility
+167.92%

Return

Best Daily Return
60 days
+259.28%
120 days
+259.28%
5 years
+259.28%
Worst Daily Return
60 days
-54.76%
120 days
-54.76%
5 years
-54.76%
Sharpe Ratio
60 days
+1.71
120 days
+1.17
5 years
-0.01

Risk Assessment

Maximum Drawdown
240 days
+78.15%
3 years
+92.85%
5 years
+98.79%
Return-to-Drawdown Ratio
240 days
-0.79
3 years
-0.30
5 years
-0.20
Skewness
240 days
+11.09
3 years
+15.50
5 years
+17.20

Volatility

Realised Volatility
240 days
+167.92%
5 years
+107.40%
Standardised True Range
240 days
+14.25%
5 years
+64.56%
Downside Risk-Adjusted Return
120 days
+375.02%
240 days
+375.02%
Maximum Daily Upside Volatility
60 days
+725.93%
Maximum Daily Downside Volatility
60 days
+208.12%

Liquidity

Average Turnover Rate
60 days
+7.42%
120 days
+4.28%
5 years
--
Turnover Deviation
20 days
+1046.50%
60 days
+422.95%
120 days
+201.32%

Peer Comparison

Healthcare Equipment & Supplies
Co-Diagnostics Inc
Co-Diagnostics Inc
CODX
5.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI